In vitro properties of surface—modified solid lipid microspheres containing an antimalarial drug: halofantrine  by Attama, Anthony A & Igbonekwu, Collins N
253Asian Pacific Journal of Tropical Medicine (2011)253-258
Document heading          doi:  
In vitro properties of surface-modified solid lipid microspheres 
containing an antimalarial drug: halofantrine
Anthony A Attama*, Collins N Igbonekwu
Department of Pharmaceutics, University of Nigeria, Nsukka 410001, Enugu State, Nigeria
 Contents lists available at ScienceDirect
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
ARTICLE INFO                           ABSTRACT
Article history:
Received 10 September 2010
Received in revised form 27 December 2010
Accepted 15 January 2011
Available online 20 April 2011
Keywords:
Solid lipid microsphere
Particle size stability
Halofantrine
Encapsulation efficiency
Release studies
In vitro evaluation
  *Corresponding author: Anthony A Attama, Department of Pharmaceutics, University 
of Nigeria, Nsukka 410001, Enugu State, Nigeria.
     Tel: +234(0)8036618204
     E-mail: aaattama@yahoo.com
    Foundation project: Funded by the International Foundation for Science (IFS), 
Sweden (IFS No. F/4467-1).
1. Introduction
  Pharmaceutical dosage forms are required to meet 
stringent standard of drug content uniformity and quality. 
This situation is to ensure that product consistently 
delivers the intended dose, thereby achieving the desired 
efficiency. However, formulation development is one 
of the most challenging aspects of pharmaceutical and 
biopharmaceutical innovations. It involves navigating the 
complexities of pharmaceutical sciences and manufacturing, 
while achieving regulatory compliance. The current 
methods of drug delivery aim to deploy medication intact to 
specifically targeted part of the body through a medium that 
can control the therapy administered by means of either a 
physiological or chemical trigger. To achieve these, drug 
delivery scientists are turning to the world of micro- and 
nanotechnology as particulate systems of drug delivery.
  Lipid based drug delivery system such as liposomes, 
microemulsions, nanoemulsions, self emulsifying systems, 
solid lipid micro- and nanoparticle are becoming more 
popular because lipid materials are easily characterized 
and can be developed for several administration routes. 
The reasons for increasing interest in lipid based system 
include: reduced plasma profile variability, better 
characterization of lipidic recipient, formulation versatility, 
choice of different drug delivery systems and improved 
ability to address the key issue of technology transfer and 
manufacture scale up[1].
  The bioavailability of orally administered lipophilic drug 
is low. There are usually several factors for this reason, 
but a particular widespread problem is poor absorption 
due to slow or incomplete dissolution in gastrointestinal 
tract. Formulation strategies to enhance solubility will 
ultimately increase bioavailability. Solid lipid based drug 
Objective: To formulate and evaluate in vitro, surface-modified solid lipid microspheres 
containing halofantrine using lipid matrix formed from goat fat and a phospholipid (P90H). 
Methods: The model drug, halofantrine in an increasing concentration of 1%, 2%, 3%, 4% 
and 5% w/w was incorporated into surface-modified solid lipid microspheres formulated by 
hot homogenization. Effect of drug concentration on the encapsulation efficiency was studied. 
The dispersion was evaluated using particle size, particle morphology, pH and encapsulation 
efficiency. The drug formulation with highest encapsulation efficiency was selected and used 
for the release studies and compared with the release from a commercial dosage form (Halfan® 
250 mg tablet, Glaxo-Smithkline, Mayenne France) using simulated gastric fluid (SGF pH 1.2), 
simulated intestinal fluid (SIF pH 7.2) and phosphate buffer (pH 6.8) as biorelevant media. 
Results were analyzed statistically and the level of significance was taken to be P<0.05). 
Results: Discrete and spherical solid lipid microspheres were produced. The particle size of 
the dispersion was low (32.48-33.87 毺m) with minimal particle growth and high encapsulation 
efficiencies (86.8%-91.0%) after 3 months. The pH of the microspheres dispersion changed 
appreciably after 3 months. In vitro release result obtained revealed sustained and controlled 
drug release from the lipid microspheres compared with the tablet dosage form. Conclusions: 
Formulation of halofantrine as solid lipid microspheres presents a better alternative to the 
conventional tablet formulation as the in vitro dissolution of the highly lipophilic halofantrine was 
highly improved.
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delivery systems have been shown to enhance dissolution 
and bioavailability of lipophilic drugs[2]. Halofantrine 
is phenanthrene methanol derivative antimalarial agent 
active against asexual form of Plasmodium falciparum[3]. 
It is practically insoluble in water but freely soluble in 
methanol and sparingly soluble in ethanol[4]. The aim of 
the present study was to formulate and evaluate in vitro 
surface-modified solid lipid microspheres drug delivery 
system of halofantrine. This novel method of formulation 
of this drug has not been reported previously. However, it 
is believed that bioavailability of halofantrine is increase 
in the presence of fats. It was worthwhile to formulate lipid 
microspheres containing halofantrine using biocompatible 
lipids and assess the properties of such dosage form in vitro. 
In different studies, halofantrine was formulated as lipid 
emulsion or microemulsion concentrate[5-8]. Phospholipid 
employed in this study has several advantages in drug 
delivery. Advantages of phospholipids formulations not 
only comprise enhanced bioavailability of drugs with low 
aqueous solubility or low membrane penetration potential, 
but also improvement or alteration of uptake and release of 
drugs, protection of sensitive active agents from degradation 
in the gastrointestinal tract, reduction of gastrointestinal 
side effects of non-steroidal anti-inflammatory drugs and 
even masking of bitter taste of orally administered drugs[2].
2. Materials and methods
2.1. Materials
  These following materials were used as procured from 
their supplier’s without further purification: methanol 
(M&B Dagenham, England), activated charcoal, sorbitol, 
polysorbate 80 (Merck, Darmstadt Germany), sodium 
hydroxide (BDH, Poole England), monobasic potassium 
phosphate, hydrochloric acid (Sigma, USA), disodium 
hydrogen phosphate, sodium dihydrogen phosphate (Sigma-
Aldrich, Germany), Halfan® 250 mg tablets (Glaxo-
Smithkline, France), thiomersal (West Yorkshire, England), 
Phospholipon 90H (Natterman, K觟ln, Germany). Goat fat 
was obtained from a batch processed in our laboratory. 
2.2.Extract ion o f  goat  fa t  and phys icochemical 
characterization
  Goat fat was extracted from the adipose tissue of Capra 
hircus by wet rendering achieved by subjecting the adipose 
tissue to moist heat by boiling with half its weight of water 
for 45 min. The molten fat was separated from aqueous 
phase after solidification. The extracted lipid was deodorized 
and decolorized to a white mass as earlier reported[9] and 
the following physicochemical properties determined using 
standard procedure[10]: melting point, refractive index, 
saponification value, unsaponifiable matter, acetyl value, 
iodine value and peroxide value.
2.3. Preparation of bulk lipid matrix
  The bulk lipid matrix consisting of 30% w/w phospholipid 
in goat fat was prepared by fusion.
2.4. Preparation of unloaded and drug-loaded solid lipid 
microspheres
  The unloaded and drug-loaded solid lipid microspheres 
were formulated by melt-homogenization technique[11] using 
Ultra-Turrax (T25 Basic, Ika Staufen, Germany) at 5 000 
rpm for 10 min. In the case of drug containing microspheres, 
the drug was first mixed with the molten lipid matrix as it is 
stable in this lipid at that temperature. The quantities used 
are stated in Table 1.
2.5. Evaluation of the formulated solid lipid microspheres
2.5.1. Determination of pH
  The pH of the different batches of the unloaded and drug-
loaded solid lipid microsphere formulations (unlyophilized 
dispersions) were measured using a pH meter (Digital 
pH Meter, Labtech) at different time intervals. Triplicate 
determinations were done.
2.5.2. Determination of particle size and morphological 
characterization of solid lipid microspheres
  The particle size of the surface-modified lipid 
Table 1
Preparation formula for unloaded and drug loaded lipid microspheres(% w/w).
Batches of lipid
microspheres
Lipid matrix Halofantrine Polysorbate 80 Sobitol Thiomersal Distilled water
U1 7.5 - 0.0 4 0.005 100
U2 7.5 - 0.3 4 0.005 100
U3 7.5 - 0.6 4 0.005 100
U4 7.5 - 1.0 4 0.005 100
U5 7.5 - 1.5 4 0.005 100
H1 7.5 1 1.5 4 0.005 100
H2 7.5 2 1.5 4 0.005 100
H3 7.5 3 1.5 4 0.005 100
H4 7.5 4 1.5 4 0.005 100
H5 7.5 5 1.5 4 0.005 100
U1 to U5 represent microspheres prepared with 0.0%, 3.0%, 3.6%, 1.0% and 1.5% w/w of polysorbate 80%, respectively; H1 to H5 represent 
microspheres containing 1%, 2%, 3%, 4% and 5% w/w of halofantrine, respectively.
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microspheres was determined by computerized image 
analysis[11] on a photomicroscope (Lieca, Germany). With 
the aid of the software in the microscope, the projected 
perimeter diameters of the particles corresponding to the 
particle sizes of the lipid microspheres were determined and 
average calculated. The particle morphologies were also 
observed and photomicrographs taken. All these were done 
in time dependent manner.
2.5.3. Drug content analysis
  A 5 mL volume of each of the drug-loaded solid lipid 
microspheres was centrifuged at 8 400 × g for 20 min to 
obtain aqueous and non-aqueous phases. A 20-fold dilution 
of the aqueous phase was prepared with methanol and the 
absorbance determined in a UV-Vis spectrophotometer 
(UNICO UV-2102 PC, USA) at a predetermined wavelength 
of 248 nm, and the encapsulation efficiency of the 
five drug-loaded formulations were calculated using 
Eqn. 1[12]. The regression equation of Beer’s plot for 
halofantrine in methanol was A = 2.448C (r2=0.977), where 
A is the absorbance of the solution and C is halofantrine 
concentration.
 EE% = 
Actual amount 
Theoretical amount
伊100   Eqn. 1
  
2.6. Preparation of biorelevant media for in vitro release 
studies
  Simulated gastric fluid (SGF, pH 1.2) without pepsin, 
simulated intestinal fluid (SIF, pH 7.2) without pancreatin 
and phosphate buffer (pH 6.8) were prepared following 
standard procedures[13,14].
2.7. In vitro release studies
  A Franz diffusion cell[15] was used for the studies. In 
each case, a finite volume of the optimized solid lipid 
microsphere formulation (H5) was placed in the donor 
compartment of the Franz diffusion cell separated from 
the receptor compartment by an artificial membrane 
(polycarbonate) (pore size 0.22 毺m). The receptor 
compartment was filled with phosphate buffer pH 6.8, SGF 
(pH 1.2) or SIF (pH 7.2) and maintained at a temperature of 
(37依1) 曟 by means of a thermostatically controlled water 
bath, with agitation provided by a magnetic stirring bar at 
50 rpm. Aliquot was removed and replaced by an equal 
volume of the receptor phase at different time interval up 
to 8 h and the samples collected analyzed for halofantrine 
content spectrophotometrically using a spectrophotometer 
(UNICO UV-2102 PC, USA). The drug content at each time 
point was calculated by reference to Beer’s calibration in 
each biorelevent medium. The formulations (Halfan® 250 mg 
tablet and halofantrine-containing surface-modified solid 
lipid microspheres) were used for in vitro release studies[16].
2.8. Data and statistical analysis
  All experiments were performed in replicates (at least, n= 
3) for validity of statistical analysis. Results were expressed 
as mean 依 SD. ANOVA and Student t-tests were performed 
on the data sets generated using Origin® for Windows, SPSS 
and SigmaPlot® 11. Differences were considered significant 
for P values < 0.05.
3. Results 
3.1. Particle size analysis
  Figures 1 and 2 show the particle size distribution of the 
unloaded and drug loaded lipid microspheres respectively. 
It was from Figure 1 that solid lipid microspheres with 
the least particle size (Batch U5) was selected for the 
formulation of drug loaded solid lipid microspheres.
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Figure 1. Time-dependent particle size analysis of unloaded solid 
lipid microspheres (mean 依 SD). 
U1 to U5 represent solid lipid microspheres prepared with 0.0%, 
3.0%, 3.6%, 1.0% and 1.5% w/w of polysorbate 80, respectively.
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Figure 2. Time-dependent particle size analysis of halofantrine-
loaded solid lipid microspheres (毺m). 
H1 to H5 represent solid lipid microspheres containing 1%, 2%, 3%, 
4% and 5% w/w of halofantrine, respectively.
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3.2. pH analysis
  The pH stability profiles for unloaded solid lipid 
microspheres containing respectively, 0.0%, 0.3%, 0.6%, 
1.0%, and 1.5% w/w of polysorbate 80 (batches U1 to U5) and 
the halofantrine-loaded solid lipid microspheres (batches 
H1 to H5) are presented in Figures 3 and 4, respectively.
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Figure 3. Time-dependent pH analysis of the unloaded solid lipid 
microsphere. 
U1 to U5 represent microspheres prepared with 0.0%, 3.0%, 3.6%, 
1.0% and 1.5% w/w of polysorbate 80, respectively.
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Figure 4. Time-dependent pH analysis of halofantrine-load solid 
lipid microspheres. 
H1 to H5 represent microspheres containing 1%, 2%, 3%, 4% and 
5% w/w of halofantrine, respectively.
3.3. Particle morphology
  Figures 5 and 6 show the photomicrographs of the 
unloaded and drug loaded solid lipid microspheres 
respect ively ,  a f ter  1  month of  s torage at  30  曟.
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Figure 5. Photomicrographs of the lipid microspheres containing no 
drug after 1 month of tormulation. 
A=0.5% w/w polysorbate 80; B=0.3% w/w polysorbate 80; C=0.6% 
w/w polysorbate 80; D=1.0% w/w polysorbate 80; and E=1.5% w/w 
polysorbate 80. Bar represents 50 毺m.
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Figure 6. Photomicrographs of the drug containing lipid microspheres 
after 1 month of formulation.
A=1.5% w/w polysorbate (80依1)% w/w halotantrine; B=1.5% w/
w polysorbate (80依2)% w/w halofamtrine; C=3% w/w halofantrine; 
D=1.5% w/w polysorbate (80依4)% w/w halotantrine; and E=1.5% w/w 
polysorbate (80依5)% w/w halotantrine. Bartepresents 50毺m.
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3.4. Encapsulation efficiency (EE%)
  The encapsulation efficiencies of the solid lipid 
microspheres are presented in Figure 7.
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Figure 7. Encapsulation efficiency (EE%).
3.5. In vitro drug release
  Figure 8 shows in vitro release of halofantrine for both 
the formulated lipid microspheres (Batch H5) and that of 
the dispersed Halfan® tablet in SGF, SIF and PB (phosphate 
buffer).
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Figure 8. Release profile of halofantrine from the formulation and the 
commercial tablet in different biorelevant media.
4. Discussion
  Particle size analysis shows that increase in concentration 
of polysorbate 80 resulted in decrease in particle size at 
constant homogenization condition. This is consistent with 
earlier findings[17]. On storage, there were minor increases 
in the particle size after 3 months indicating high particle 
size stability, although, the particle sizes were low after 
formulation. The particle sizes were between (18.6依2.1) 毺m 
to (29.3依2.9) 毺m for the unloaded solid lipid microspheres 
after 3 months and (35.9依1.4) 毺m to (20.9依1.1) 毺m for 
the drug loaded lipid microspheres. It was also observed 
that there was increase in particle size on drug loading, 
which also increased as the drug content increased. This 
indicated that the drug was located mostly in the solid core 
of the microsphere since it is highly lipophilic. Particle 
size, particle size distribution and stability are a major 
issue considered by formulation scientists when formulating 
dispersed systems[18,19].
  The pH stability profiles show that the pH of the unloaded 
solid lipid microspheres significantly changed (P<0.05) 
after storage. The pH profile of the drug-loaded solid 
lipid microspheres of the different batches showed the 
pH values were fairly constant between 24 h and 1 month 
presenting values of 6.1依1.2 to 6.9依1.6 and 6.1依3.1 to 7.3 
依2.1 respectively. The pH values were affected by drug 
loading as there was a significant difference (P<0.05) 
between the pH values of the unloaded and drug loaded 
solid lipid microspheres. One has to be aware that since 
this formulation is particulate in nature and is dispersed in 
aqueous medium, particle surface pH in some systems may 
be 2 to 3 units different from the pH of the bulk because of 
double layer forces of attraction/adsorption of other ions in 
the continuous phase[20].
  The photomicrographs of the solid lipid microspheres 
revealed that they are crystalline in nature, spherical and 
uniform with a smooth surface. The particles appeared to 
be aggregate in nature without evidence of any collapsed 
particles. It should be noted that the micrograph presents 
the particles in two dimensions and particles viewed edge-
on may not appear spherical.
  The encapsulation efficiencies of the solid lipid 
microspheres indicated very high EE%. It can be inferred 
that the encapsulation efficiency increased with the 
increasing concentration of drug loaded into the lipid 
microspheres and also with duration of time. The significant 
increase (P<0.05) in the EE% with time indicates that after 
preparation, the lipid microspheres remained fluid. Analysis 
of the drug content within 24 h would be erroneous since 
complete crystallization had not occurred. Migration of 
drug from the aqueous phase into the lipid microspheres 
continued until complete crystallization had reached 
because the drug is highly lipophilic. The percentage of 
drug entrapped is also dependent upon the physicochemical 
properties of the drug, the nature of the lipid components 
selected, the solvent and the manner in which the 
components were combined.
  In the in vitro release studies of halofantrine for both 
the formulated lipid microspheres (Batch H5) and that 
of the dispersed Halfan® tablet in SGF, SIF and PB 
(phosphate buffer), it was observed that halofantrine 
release was greater from the lipid microspheres than from 
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the tablet formulation (crushed) at the end of the release 
period. This was as a result of solubility enhancement 
by the phospholipid-containing solid lipid microsphere. 
Phospholipid formulations not only enhance bioavailability 
of drugs with low aqueous solubility or low membrane 
penetration potential, but also improve or alter uptake 
and release of drugs[2,21,22]. The release profile revealed 
that the formulations tested in different biorelevant media 
had different maximum release. The novel formulation 
containing 5% w/w halofantrine released maximally after 7 h 
in phosphate buffer (pH 6.8), while the commercial dosage 
form could only achieve about 30% maximum release in 
same media after 7 h. There was also a controlled release of 
halofantrine from the novel lipid microsphere formulation 
compared with the commercial dosage form. There was 
no burst release from the novel lipid microsphere dosage 
form. Release followed this order: PB > SIF > SGF. The 
decreased release rate of halofantrine from the tablet may be 
attributed to the granular nature of Halfan tablet and it has 
to dissolve before releasing the drug and also the solubility 
of the drug in the release media. Release studies were 
conducted in different biorelevant media to ascertain the 
possible behaviour of the formulation as it transits the entire 
gastrointestinal system since the formulation is intended for 
oral administration.
  The solid lipid microspheres containing halofantrine 
exhibited an excellent release profile compared with the 
commercial table dosage form (Halfan®). This was as a 
result of the increase in solubility of the lipophilic drug. 
It is envisaged that there would be controlled release of 
halofantrine in vivo from this novel dosage form and this will 
ultimately enhance boavailability and a better therapeutic 
effect will be obtained. It is recommended that further 
research into use of a lipid matrix and phospholipid in the 
formulation of halofantrine be embarked upon.
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